The host response to Clostridium difficile infection in antibiotic-treated mice is characterized by robust recruitment of Gr-1 + cells, increased expression of inflammatory cytokines including tumour necrosis factor-a (TNF-a), and the development of severe epithelial damage. cytes: however, we observed no protection from the development of severe pathology or reduction in expression of the pro-inflammatory cytokines Il1b, Il6, Il33 and Tnfa following anti-Gr-1 treatment. By contrast, anti-TNF-a treatment did not affect Gr-1 + cell recruitment, but was associated with increased expression of Il6 and Il1b. Additionally, Ffar2, Ffar3, Tslp, Tff and Ang4 expression was significantly reduced in anti-TNF-a-treated animals, in association with marked intestinal histopathology. These studies raise the possibility that TNF-a may play a role in restraining inflammation and protecting the epithelium during C. difficile infection.
Introduction
The inflammatory signals that support leucocyte recruitment, intestinal histopathology and inflammatory cytokine production during Clostridium difficile infection are still not completely understood. Recent studies have identified key roles for Myeloid Differentiation Primary Response 88, Nucleotide Binding Oligomerization Domain 1, and Caspase Recruitment Domain Containing Protein in promoting neutrophil recruitment and the production of inflammatory cytokines in response to C. difficile infection. [1] [2] [3] Additionally, signalling of Toll-like
I M M U N O L O G Y O R I G I N A L A R T I C L E
receptors 4 and 5 has been shown to prevent the development of severe intestinal histopathology during C. difficile infection. 4, 5 However, the role of tumour necrosis factora (TNF-a) in promoting epithelial damage, leucocyte recruitment and inflammatory cytokine expression during C. difficile infection has yet to be investigated.
Antibiotic pre-treatment is required to infect conventional mice with C. difficile. [1] [2] [3] [4] [6] [7] [8] [9] [10] [11] However, antibiotic treatment is also capable of modulating inflammatory responses and immune cell function. [12] [13] [14] [15] [16] In vitro studies have demonstrated reduced expression of inflammatory mediators from monocytes stimulated with live fungal 15 or heat-killed bacterial 13 cells following moxifloxacin and co-trimoxazole treatment, respectively. Macrolide antibiotics can also affect inflammatory functions of pulmonary epithelial cells and modulate TNF-a, interleukin-8 (IL-8) and Granulocyte-macrophage colony stimulating factor production by these cells. [16] [17] [18] [19] Ceftriaxone is a third-generation cephalosporin with bactericidal activity against both Gram-positive and Gram-negative bacteria. [20] [21] [22] Cefoperazone, another third-generation cephalosporin, can markedly alter the composition of the intestinal microbiota and render mice susceptible to C. difficile infection. 8, 10 In the current study, we investigated the ability of ceftriaxone to permit C. difficile infection, and whether ceftriaxone treatment alone was sufficient to induce colonic inflammation.
Tumour necrosis factor-a promotes leucocyte recruitment and the expression of inflammatory cytokines during mucosal inflammation. [23] [24] [25] TNF-a expression is significantly increased during acute C. difficile colitis, 9 and macrophage TNF-a production is also enhanced by exposure to C. difficile toxins. 26 Gr-1 is an epitope found on both Ly6C and Ly6G, and is expressed on neutrophils, inflammatory monocytes, and plasmacytoid dendritic cells. 9, [27] [28] [29] Gr-1 + cells are recruited in large numbers to the large intestine in response to C. difficile infection, [1] [2] [3] 9 and protect against bacterial dissemination and mortality. 2, 3 However, much remains unknown about the contributions of Gr-1 + cells and TNF-a in promoting intestinal histopathology, leucocyte recruitment, and the expression of inflammatory cytokines during C. difficile colitis.
Materials and methods

Bacterial culture and growth conditions
Clostridium difficile was prepared for infection as described previously. 8, 10 Briefly, an overnight culture of C. difficile strain VPI 10463 (ATCC 43255) was backdiluted 1 : 10 in fresh brain-heart infusion broth supplemented with 0.1% cysteine and grown for 4-6 hr. The culture was then collected, washed three times in deoxygenated PBS, and diluted to the desired dose. Mice were challenged via oral gavage. The inoculum was serially diluted and plated on brain-heart infusion supplemented with 0.1% cysteine to confirm dosage. Clostridium difficile was grown and prepared for gavage in a Coy anaerobic chamber (Coy Laboratory Products, Grass Lake, MI).
Animals and housing
C57BL/6 male mice aged 5-9 weeks at the time of antibiotic pre-treatment were used in the current study. All experiments were conducted under a protocol approved by the University Committee on Use and Care of Animals at the University of Michigan. All mice were purchased directly from Jackson Laboratories (Bar Harbor, ME) or obtained from an in-house colony founded by Jackson breeders. Mice were housed with autoclaved bedding, food and water. All animal manipulations were carried out in a laminar flow hood.
Antibiotic treatment and infection
For ceftriaxone and C. difficile infection studies, mice were treated with ceftriaxone (0Á5 g/l) (Sigma, St Louis, MO) given ad libitum in their drinking water for 4 days. Antibiotic water was replaced every other day. Mice were then given a 2-day recovery period on drinking water without antibiotic before infection with C. difficile as described previously. 8, 10 Ceftriaxone-treated mice were given the antibiotic regimen only, and untreated animals were not manipulated at all. For C. difficile infection studies, mice received 5Á06 AE 0Á31 Log 10 colony-forming units vegetative C. difficile via oral gavage on day 2 ( Fig. 1) . Clostridium difficile-infected animals were monitored for signs of severe disease (hunched posture, lethargy, weight loss exceeding 20% of baseline body weight) and were humanely killed if moribund. All surviving animals were killed on day 4 for subsequent analysis (Fig. 1) .
Antibody administration
Mice were given intraperitoneal injections of 250 lg of anti-TNF-a monoclonal antibody (mAb; clone MP6-XT3) 1 day before infection with C. difficile or injections of 250 lg of anti-Gr-1 mAb (clone RB6-8C5) 1 day before and 1 day after infection. Mouse serum (Sigma) injections were administered to control mice.
Histology
Colonic tissue was collected from the midpoint of the colon and either flash-frozen in liquid nitrogen for subsequent DNA extraction or stored in RNAlater (Life Technologies, Grand Island, NY) for RNA analysis. Whole colons were excised from representative mice and prepared for histological analysis as described previously. 8, 10 Cassettes were processed, paraffin embedded, 
Histopathological examination
Histological sections were coded, randomized and scored in a blinded manner. The slides were first scored categorically on a 0-5 scale for epithelium damage and for inflammation, using defined criteria. Epithelium damage was scored as follows: 0, intact epithelium; 1, minimal, scattered goblet cell loss with no significant epithelium destruction and no histologically defined loss of surface integrity; 2, widespread moderate goblet cell loss with no significant epithelium destruction and no histologically defined loss of surface integrity; 3, moderate to extensive widespread goblet cell loss with scattered epithelium destruction and histologically defined loss of surface integrity; 4, extensive epithelium and goblet cell destruction with histologically defined loss of surface integrity; 5, severe epithelium destruction and goblet cell destruction with widespread histologically apparent loss of surface integrity. Inflammation was scored as follows: 0, no inflammation; 1, minimal multifocal leucocytic infiltrates; 2, moderate multifocal leucocytic infiltrates and low level oedema (greater submucosal involvement); 3, significant multifocal leucocytic infiltrates, oedema, submucosal involvement; 4, extensive multifocal leucocytic infiltrates, oedema, extensive submucosal involvement; 5, severe multifocal leucocytic infiltrates, extensive oedema and submucosal involvement with luminal involvement and/or abscess formation. The slides were then assigned an overall score using a rank-order scoring system. The total of both categorical scores (epithelium damage and inflammation) were used to rank all the slides in the study in order of increasing severity of histopathological changes (1 = least, 16 = most). This method offers significant advantages over straight categorical scoring systems for comparing histological changes between groups and has been previously reported for scoring C. difficile-induced intestinal pathology. 10, 30, 31 RNA isolation and expression analysis RNA was isolated and purified from colonic tissue as described previously. 9 RNA quality was assessed using an Agilent bioanalyzer (Agilent Technologies, Santa Clara, CA), and the concentration of RNA was assessed using a Nanodrop instrument (Thermo Fisher Scientific, Waltham, MA). Complementary DNA was generated using the RT 2 First Strand kit (Qiagen, Valencia, CA), and gene expression was then determined using RT 2 PCR cards (Qiagen). To account for any variation between RT 2 PCR cards, cross-card normalization was performed as described previously. 9, 32 The mean Ct values of two internal control genes was subtracted from the Ct of the gene in question to generate DCt (dCt) values. 33 The 2
ÀddCt method was used to calculate fold change gene expression for all comparisons. 34 All reactions were run on a LightCycler 480 (Roche, Indianapolis, IN).
DNA isolation, amplicon library preparation, 454 pyrosequencing and microbiome community analysis All procedures and analyses were performed as previously described. 9 Briefly, DNA was isolated from rinsed colonic tissue and V3-V5 16S ribosomal RNA gene amplicon libraries were generated. They were then sequenced on a Roche 454 GS Junior Titanium platform according to the manufacturer's specifications. Bacterial 16S rRNA gene sequences were processed using the microbial ecology software suite MOTHUR 35 to generate operational taxonomic units (OTUs) at a 3% level of difference (approximating species-level differences). These data were then imported into the software package R and analysed using the R add on-package VEGAN.
36 Rank abundance plots were generated by selecting for the OTUs that contributed to > 0Á5% of the population. The content of each treated tissue was ordered according to the average rank order of its untreated counterpart. Taxonomic classification of an OTU was assigned within MOTHUR by identifying the consensus sequence of the OTU and assigning taxonomy using a Bayesian classifier trained on an Ribosomal Database Project training set (classify.otu).
Quantification of C. difficile colonization
Mucosal C. difficile colonization was determined using a species-specific quantitative PCR of DNA isolated from colonic tissue. The C. difficile-specific qPCR was performed as described previously. 8, 37 All reactions were carried out in a total volume of 10 ll. Each reaction contained 2 ll of template primers, 6Á25 pmol forward and reverse tcdB primers, and 1 pmol tcdB probe. The cycling conditions and probe and primer sequences are identical to those used previously. 8 Raw Ct values were normalized to signal from a single-copy host internal control gene to generate dCt values. 8, 34 The dCt values were then converted to 'C. difficile genomes/g tissue' using a standard curve generated with known amounts of vegetative C. difficile and colonic tissue.
Gr-1 + Cells and TNF during C. difficile Colitis
Colonic leucocyte isolation
Colonic leucocytes were isolated as described previously 2,9,38 with modification. Colonic tissue was minced with serrated scissors and incubated in 20 ml of Hanks' balanced salt solution supplemented with 2Á5% fetal bovine serum, 5 mM EDTA and 1 mM dithiothreitol for 20 min at 37°. After washing, tissue was incubated in 20 ml Hanks' balanced salt solution supplemented with 2Á5% fetal bovine serum, 400 U/ml collagenase type 3 (Worthington Biochemical, Freehold NJ), and 0Á5 mg/ml DNase I (Roche) for 60 min at 37°. Samples were then resuspended in 20% Percoll (Sigma) in PBS, and centrifuged at 900 g for 30 min at room temperature. The resulting single-cell suspensions were stained for analysis of cell surface marker expression via flow cytometry.
Flow cytometry and staining
Flow cytometric staining was performed as described previously. 9 Briefly, cells were blocked with unlabelled FcRIII/II, and subsequently stained with fluorescently labelled antibodies for 30 min. Cells were then washed and finally suspended in stabilizing fixative (BD Biosciences, San Jose, CA). All data were collected on a three-laser Canto II using FACSDIVA software (BD Biosciences). All subsequent analysis was performed using FLOWJO (Treestar, Ashland, OR). The following antibodies were used for flow cytometric analysis of intestinal leucocytes. CD11c (clone HL3), CD45 (clone 30-F11), CD11b (clone M1/70), Gr-1 (clone RB6-8C5), and Ly6C (clone AL-21) as well as FcRIII/II (clone 2Á4G2). All antibodies were purchased from BD Biosciences and Biolegend (San Diego, CA).
Statistical analysis
Unpaired two-tailed t-tests were used to identify statistically significant differences in gene expression between untreated and ceftriaxone-treated mice. For all other analyses, statistically significant changes were identified using a one-way analysis of variance with Tukey's post hoc test for multiple comparisons. For all quantitative PCR data (colonic gene expression and C. difficile colonization), statistical analysis was performed on normalized dCt values. Significance was set at P ≤ 0Á05 in all analyses.
Results
Effect of ceftriaxone treatment on the colonic microbiota
To assess the effect of ceftriaxone treatment on the diversity and membership of the colonic microbiota, animals were given ceftriaxone (0Á5 g/l) in their drinking water for 4 days and analysed 4 days later (Fig. 1a) . 454-pyrosequencing analysis of 16S amplicon libraries generated from colonic tissue from untreated and ceftriaxone-treated mice allowed for characterization and comparisons of the colonic mucosa-associated microbiota between groups. 39 This analysis revealed that 4 days of ceftriaxone treatment was sufficient to significantly decrease the diversity of the mucosa-associated microbiota, compared with untreated mice, at 4 days post-antibiotic (Fig. 1b) . While untreated animals possessed a complex microbiota comprised primarily of members of the phyla Bacteroidetes and Firmicutes (Fig. 1c) , ceftriaxone treatment was associated with a marked shift in the membership of the community towards a composition dominated by a single Firmicute; Enterococcaceae (Fig. 1d) . These experiments demonstrated that ceftriaxone treatment was sufficient to significantly decrease the diversity and markedly alter the membership of the colonic microbiota even 4 days after the cessation of antibiotic treatment.
Effect of ceftriaxone treatment on colonic gene expression
To investigate the effect of ceftriaxone treatment and the associated loss of microbial diversity on immune regulation the colonic mucosa, quantitative RT-PCR was used to examine colonic cytokine expression following ceftriaxone treatment. Ceftriaxone treatment was associated with significantly increased expression of the chemokines Ccl5 and Cxcl9, and significantly decreased expression of Ccl11, Ccl3 and Cxcl2 (Fig. 2a,b) . Additionally, Il2, Il10, Il5 and Il3 expression was all significantly increased following ceftriaxone treatment, while expression of Il23a, Il17f, Il1b, Il17a, Tgfb and Slpi was decreased (Fig. 2c-e) . Examination of histopathological sections from the colons of ceftriaxone-treated mice revealed no evidence of cellular infiltration or inflammation in these animals (see Supporting information, Figure S1 ). Taken together, these data demonstrate that ceftriaxone treatment alone induces significant changes in the cytokine expression pattern in the colonic mucosa but does not result in overt inflammatory histopathological changes.
Clostridium difficile infection following ceftriaxone treatment
To determine if ceftriaxone treatment was sufficient to permit colonization and infection by C. difficile, ceftriaxone-treated mice were challenged with vegetative cells (10 5 colony-forming units) from C. difficile strain VPI 10463 2 days after the cessation of ceftriaxone treatment and were followed for an additional 2 days (Fig. 1a) . Significant colonization by C. difficile was detected in the colonic mucosa of infected mice via quantitative PCR by 2 days post challenge (Fig. 3a) . Colonization did not cause a shift in the membership (Fig. 1c-e) or diversity (Fig. 1b) of the colonic microbiota beyond that attributable to ceftriaxone treatment alone. Clostridium difficile colonization of ceftriaxone-treated mice resulted in an influx of inflammatory cells into the colon and marked epithelial damage, indicative of active infection (Fig. 4) . Taken together, these data demonstrate that ceftriaxone treatment renders mice susceptible to C. difficile colonization with the concomitant development of colitis.
Host responses to C. difficile colitis
In order to characterize the mucosal response to C. difficile colitis following ceftriaxone treatment, colonic gene expression was examined. Infection with C. difficile was associated with increased expression of Inos, Slpi, Il1b, Il6, Il17f, Ifng, Il17a, Il22, Il2, Il33 and Tnfa (Fig. 7 and 8c) . Expression of Il18, Il23, Il12, Il3, Il4, Il5, Il13, Il10, Tgfb and Ang4 was not induced in response to C. difficile infection (Fig. 7 and 8c) . Consistent with the robust cellular recruitment observed in histological sections from C. difficile-infected mice (Fig. 4) , there was increased expression of the CC chemokines Ccl2, Ccl3, Ccl4, Ccl5 and Ccl7, but not Ccl11 or Ccl24 (Fig. 6a,b ) and the expression of the CXC chemokines Cxcl1 and Cxcl2, as well as the neutrophil stabilization factors Csf2 and Csf3 were also increased (Fig. 6c,d) . Hence, these data indicate that the mucosal response to C. difficile infection is characterized by increased expression of CC and CXC chemokines and inflammatory cytokines including Il1b, Il6, Il17f and Tnfa.
Flow cytometry was used to further delineate the leucocyte populations recruited to the colon following C. difficile infection. Analysis of the side scatter (SSC) and forward scatter (FSC) parameters of CD45 + leucocytes revealed a drastic influx of FSC Mid SSC High leucocytes in response to C. difficile infection (Fig. 5a) To determine the role of Gr-1 + cells in supporting the mucosal inflammatory response to C. difficile infection, animals were treated with an anti-Gr-1 mAb (clone RB6-8C5) 1 day before and 1 day after C. difficile infection (Fig. 1a) . There was a marked reduction in the frequency of CD11b
High CD11c
Low inflammatory myeloid cells, as well as a reduction in both the Ly6C
Mid Gr-1 High neutrophil and Ly6C
High Gr-1 Mid monocyte populations following anti-Gr-1 treatment (Fig. 5b,c) . However, anti-Gr-1 treatment had no effect on C. difficile levels in the colonic mucosa (Fig. 3a) .
Compared with C. difficile infection alone, Il5, Il12 and Il22 expression was significantly reduced, and Il3 expression was significantly increased, in C. difficile-infected anti-Gr-1-treated mice (Fig. 7c-e) . However, expression of Il1b, Il6, Csf2, Csf3, Tnfa and Il33 was unchanged following anti-Gr-1 treatment (Fig. 6 and 7) . Expression of Cxcl1, Cxcl2, Ccl2 and Ccl3 was also not significantly affected by anti-Gr-1 treatment (Fig. 6a,c) . Anti-Gr-1 treatment did not protect against the colonic histopathology that developed during the normal course of infection ( Fig. 3b and 4) . Taken together, these data indicate that the expression of CC and CXC chemokines, the expression of inflammatory cytokines including Tnfa, Il1b and Il6, and the development of severe colonic histopathology during C. difficile colitis are all independent of the presence of Gr-1 + cells within the colon.
The role of TNF-a during C. difficile colitis
To examine the role of TNF-a in promoting inflammatory myeloid cell recruitment and epithelial damage in response to C. difficile infection, mice were treated with a TNF-a neutralizing mAb (clone MP6-XT3) 1 day before infection (Fig. 1a) . Clostridium difficile colonization within the colonic mucosa was equivalent between anti-TNF-a-treated and C. difficile-infected animals (Fig. 3a) . There was near identical recruitment of CD11b
Low inflammatory myeloid cells following anti-TNF-a treatment compared with that seen in response to C. difficile infection alone (Fig. 5b) . Ly6C
Mid Gr-1
High neutrophil and Ly6C
High Gr-1
Mid monocyte frequencies were also unchanged following anti-TNF-a treatment (Fig. 5c ). Consistent with this observation, Cxcl1, Cxcl2, Ccl2 and Ccl3 expression was not reduced in these mice (Fig. 6a,c) . While the expression of Il33, Ifng and Il17f was not significantly reduced by anti-TNF-a treatment, expression of Mif, Il1b and Il6 was all significantly increased following anti-TNF-a treatment ( Fig. 6d and 7) . Furthermore, expression of Ccl5, Il5 and Il22 was all significantly lower in anti-TNF-a-treated mice ( Fig. 6b and 7d ,e). Epithelial damage was prominent in anti-TNF-a-treated mice (Fig. 4) and anti-TNF-a treatment was associated with more severe colonic histopathology (Fig. 3b) . Anti-TNF-a treatment was also associated with a significant decrease in the expression levels of the colonic goblet cell gene Ang4, the free fatty acid receptors Ffar2 and Ffar3, epithelium-derived effector and signal molecules encoded by Tslp, Tff, Defb3 and Lyz1, in addition to a trend toward higher expression levels of Slpi compared with C. difficile infection alone (Fig. 8) . Additionally, there was a trend towards decreased expression of the goblet cellspecific gene Muc2 after anti-TNF-a treatment (Fig. 8a) . Taken together, these data indicate that anti-TNF-a treatment was associated with enhanced colonic epithelial dysfunction/destruction and can augment the epithelial inflammatory milieu during C. difficile infection.
Discussion
Together, these data demonstrate that ceftriaxone-treated mice are a robust model for investigating the innate acute inflammatory response to C. difficile infection. In addition to altering the composition of the colonic microbiome, ceftriaxone treatment alone was also capable of modulating colonic cytokine and chemokine expression 4 days after the cessation of antibiotic treatment. While ceftriaxone treatment was associated with significantly altered expression of several genes induced during C. difficile colitis, the induction of the inflammatory cytokines and chemokines associated with C. difficile infection was significantly greater than that seen with ceftriaxone treatment alone (see Supporting information, Figure S2 ). Additionally, ceftriaxone treatment alone did not produce any histopathological changes in the colonic mucosa (see Supporting information, Figure S1 ). Hence, while ceftriaxone treatment is capable of modulating colonic gene expression, we propose it is not a confounding factor in evaluating the host inflammatory response in this model of infectious colitis.
Anti-TNF-a treatment was associated with an augmented epithelial inflammatory response to C. difficile infection. Previous studies have reported a role for TNF-a signalling in promoting myeloid cell recruitment during mucosal inflammation. 23, 24 TNF-a can enhance the expression of CCL3 during chemically induced pulmonary inflammation, 24 and interference with TNF-a signalling reduces neutrophil recruitment in response to acute allergic airway inflammation. 23 TNF-a can contribute to inflammatory cytokine expression and tissue damage Gr-1 + Cells and TNF during C. difficile Colitis during mucosal inflammation. 25, 40 Directly applicable to gastrointestinal inflammation, during 2,4,6-trinitrobenzenesulphonic acid colitis, TNF-a signalling promotes both IL-18 and TNF-a expression as well as the development of intestinal histopathology. 25 Anti-TNF-a treatment had no effect on Cxcl1, Cxcl2, Ccl2 and Ccl3 expression during C. difficile colitis, and we observed no reduction in neutrophil and monocyte recruitment under these conditions. However, colonic expression of Il1b and Il6 was increased following anti-TNF-a treatment. Hence, despite its relatively low level of expression, TNF-a is involved in the inflammatory response during C. difficile colitis but the induction of CC and CXC chemokines and subsequent myeloid cell recruitment during infection are largely TNF-a-independent. While TNF-a is generally held to be a pro-inflammatory mediator that can participate in indirect epithelial damage, there is precedent for an epithelium cytoprotective role for this cytokine, as our data suggest may occur in this infection model. [41] [42] [43] TNF-a signalling can protect against severe intestinal histopathology during Citrobacter rodentium infection. 41 Furthermore, cellular infiltration and intestinal epithelial damage during DSS colitis are enhanced in the absence of TNF-a. 42, 43 Following anti-TNF-a treatment we observed decreased expression of the free fatty acid receptors Ffar2 and Ffar3, as well as Defb3, Lyz1 and Tslp, consistent with the severe colonic epithelial damage present in these animals. Anti-TNF-a treatment was also associated with significantly decreased expression of Ang4 and a trend towards decreased expression of Muc2, two genes whose expression is specific to goblet cells within the gastrointestinal tract, [44] [45] [46] suggesting reduced goblet cell function. Additionally, colonic histopathology was most severe following anti-TNF-a treatment. Hence, our data are consistent with these other models of colitis where TNF-a plays a role in protecting the colonic epithelium from damage during inflammation, and suggests an epithelial-protective role for TNF-a during acute, severe C. difficile infection.
One model that could explain the association between anti-TNF-a treatment and increased inflammatory responses and epithelial damage is that TNF-a signalling may restrain host inflammatory responses by promoting the clearance of translocated commensal bacteria. Previous studies have demonstrated the dissemination of commensal bacterial to distal sites during C. difficile infection, 1,2 and have also suggested a role for these translocated bacteria in promoting innate inflammatory responses, including the production of IL-1b.
1 TNF-a signalling can activate macrophages and enhance their bactericidal capacity, 47 and mucosal macrophages represent a large resident population within the colonic lamina propria with the capacity to eliminate invading bacteria. 48 Hence, in the absence of TNF-a signalling, translocated commensal bacteria may be less efficiently cleared by macrophages within the colonic lamina propria, leading to increased activation of inflammatory pathways and enhanced colonic tissue damage.
Despite Gr-1 + Cells and TNF during C. difficile Colitis to C. difficile infection, we observed no reduction in colonic expression of CC and CXC chemokines or proinflammatory cytokines including Il1b, Il6, Il33 and Tnfa following anti-Gr-1 treatment. Neutrophil recruitment is commonly associated with the development of inflammation at mucosal sites 23, 49, 50 and neutrophils are a welldocumented source of inflammatory cytokines, including IL-6, as well as the neutrophil chemokine IL-8. [51] [52] [53] While several studies have investigated the role of neutrophils in reducing host mortality and preventing the translocation of bacteria during C. difficile infection, 2, 3 to our knowledge the role of neutrophils as a cellular source of chemokine and cytokine expression has not been extensively investigated. Despite effective depletion of both neutrophils and monocytes following our anti-Gr-1 treatment, colonic CC and CXC chemokine expression as well as Il1b, Il6, Il33 and Tnfa expression was unchanged. Consistent with the significant reduction in Il22 expression, a cytokine with a vital role in promoting wound healing and preventing epithelial damage at mucosal sites, [54] [55] [56] we observed no protection from intestinal epithelial damage in anti-Gr-1-treated mice. Taken together, our data strongly suggest that the recruited Gr-1 + populations, including neutrophils, are not responsible for the robust inflammatory cytokine expression or epithelial damage observed during C. difficile infection.
One potential explanation for our observation that depletion of Gr-1 + cell populations had minimal effect on colonic cytokine and chemokine expression is that Gr-1 + cells, including neutrophils, are not a major cellular source of these inflammatory mediators during the host response to C. difficile colitis. A recent study has reported decreased intestinal IL-1b and CXCL1 production following neutrophil depletion. 1 However, that study used a less severe model of disease with 100% survival of infected animals at 5 days-post infection, 1 while the model used in the current study, similar to other models based on the third-generation cephalosporin cefoperazone, 8, 10 resulted in high morbidity by 2 days post infection. Hence, in the context of such an overwhelming infection, alternative pathways and sources of inflammatory cytokine expression may respond and effectively supersede the cytokine production by neutrophils observed in less severe models. Additionally, Hasegawa et al.
1 used a combination of seven antibiotics to permit C. difficile infection, compared with the single antibiotic, ceftriaxone, used in the current study. These two antibiotic treatments will likely result in different colonic microbial communities, whose members may differentially stimulate host cell subsets and result in the activation of distinct inflammatory pathways in response to the same challenge. 
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